Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in North Brunswick, New Jersey. Show more

77 Robinson Road, Singapore, 068896, Singapore

https://www.adlainortye.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

966.6M

52 Wk Range

$0.88 - $17.25

Previous Close

$14.75

Open

$14.69

Volume

308,574

Day Range

$14.55 - $16.02

Enterprise Value

736.7M

Cash

8.056M

Avg Qtr Burn

N/A

Insider Ownership

0.57%

Institutional Own.

45.20%

Qtr Updated

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Buparlisib/AN2025 + Paclitaxel Details Cancer, Head and neck squamous cell carcinoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Buparlisib/AN2025 in comb w/chemoradiotherapy and radiotherapy Details Cancer, Rectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AN0025 + definitive chemoradiotherapy (dCRT) Details Cancer, Esophageal cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AN9025 (Pan-RAS Inhibitor) Details RAS-Mutant Advanced Or Metastatic Solid Tumors	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AN4005 (PD-L1 Inhibitor) Details Cancer, Advanced Tumors	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AN8025 (Tri-Specific Antibody Fusion) Details Cancer, Advanced Solid Tumors	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AN4035 (Pan-RAS ADC) Details CEACAM5-Enriched RAS-Addicted Solid Tumors	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.